Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fulgent Genetics Inc (NQ: FLGT )

19.64 -0.46 (-2.29%)
Streaming Delayed Price Updated: 3:56 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fulgent Genetics Inc

< Previous 1 2 3 4 Next >
Fulgent Genetics Q3 Revenues More Than Double; Raises FY21 Outlook
Fulgent Genetics Inc (NASDAQ: FLGT) reported Q3 sales of $227.9 million, +124% Y/Y, beating the consensus of $264 million primarily driven by sales of its COVID-19... 
Via Benzinga
Fulgent Genetics, Inc. Common Stock (FLGT) Q3 2021 Earnings Call Transcript
FLGT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Fulgent Genetics: Q3 Earnings Insights
Fulgent Genetics (NASDAQ:FLGT) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
3 Genomics Stocks That Could Soar 60% or Better, According to Wall Street
The genomic revolution is upon us and these stocks could be great vehicles for investors who want to take advantage of it. 
Via The Motley Fool
Fulgent Genetics Stock Meets 80-Plus Relative Strength Rating Benchmark
A Relative Strength Rating upgrade for Fulgent Genetics shows improving technical performance. 
Via Investor's Business Daily
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
What's Going on With Fulgent Genetics?
The company is leveraging success with its COVID-19 tests to position itself better for a post-pandemic world. 
Via The Motley Fool
Exposures COVID-19
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Can This Stock Grow Despite a COVID Testing Decline?
Fulgent has capitalized on COVID-19 testing, but even though this segment of its business might slow, there are plenty of reasons to own the company. 
Via The Motley Fool
Exposures COVID-19
These 3 Top Healthcare Stocks Are Screaming Buys Right Now
If the market crashes these companies could be insulated. 
Via The Motley Fool
3 Unstoppable Healthcare Stocks to Buy With Just $1,000
It doesn't take much when you buy great companies and let them grow. 
Via The Motley Fool
The 1 Stock I'd Buy Right Now
The pandemic isn't over yet. 
Via The Motley Fool
Exposures COVID-19
Fulgent Genetics's Return on Invested Capital Overview
Pulled from Benzinga Pro data, Fulgent Genetics (NASDAQ:FLGT) posted Q2 earnings of $98.90 million, an increase from Q1 of 62.95%. Sales dropped to $153.62 million, a 57.26%... 
Via Benzinga
10 Million Reasons I'm Not Selling Fulgent Genetics
The company is about to shock Wall Street. 
Via The Motley Fool
Exposures COVID-19
Have $500? 3 Absurdly Cheap Healthcare Stocks Long-Term Investors Should Consider Buying Right Now
Everyone loves a discount. 
Via The Motley Fool
2 Types of Growth Stocks Investors Should Be Holding in Their Portfolios Today
Hedging against COVID-19 could prove to be crucial in keeping your portfolio safe. 
Via The Motley Fool
Topics Economy
Exposures COVID-19 Economy
85 Biggest Movers From Yesterday
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX... 
Via Benzinga
Why Shares of Fulgent Genetics Are Plunging Today
Spectacular quarterly results were not enough to satisfy investors' appetites. 
Via The Motley Fool
Topics Death
Exposures COVID-19 Death
54 Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Arcturus Therapeutics (NASDAQ:ARCT) shares rose 25.93% to $60.75 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5... 
Via Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
28 Stocks Moving in Tuesday's Pre-Market Session
Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares rose 38.6% to $66.88 in pre-market trading after the company reported better-than-expected Q2 earnings and also... 
Via Benzinga
Fulgent Genetics Stock Falls As Q2 Earnings Miss Street Estimates; Lowers FY21 Sales Outlook
Fulgent Genetics Inc (NASDAQ: FLGT) reported after the close of the market on Monday that its second-quarter revenues increased nearly ninefold, driven primarily by... 
Via Benzinga
Topics Earnings
Exposures Financial
Fulgent Genetics, Inc. Common Stock (FLGT) Q2 2021 Earnings Call Transcript
FLGT earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Fulgent Genetics Q2 Earnings
Shares of Fulgent Genetics (NASDAQ:FLGT) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 1400.00% year... 
Via Benzinga
Why Shares of Fulgent Genetics Rose 77% in the First Half of 2021
The stock has traded with the ebbs and flows of COVID cases, but its testing has consistently delivered for its impressive list of customers. 
Via The Motley Fool
3 Things About Fulgent Genetics That Smart Investors Know
Few companies had bigger tailwinds from COVID-19. What comes next could be even more exciting. 
Via The Motley Fool
Exposures COVID-19
5 Stocks to Own for the Surge in Coronavirus Variants
Despite easing restrictions, COVID is going to be around a lot longer than many think. 
Via The Motley Fool
Exposures COVID-19
3 Stocks I'd Buy if the Market Crashes
A steep sell-off is required for these stocks to become bargain buys. 
Via The Motley Fool
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.